BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35507170)

  • 1. Genome Engineering of Hematopoietic Stem Cells Using CRISPR/Cas9 System.
    Devaraju N; Rajendiran V; Ravi NS; Mohankumar KM
    Methods Mol Biol; 2022; 2429():307-331. PubMed ID: 35507170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome editing in human hematopoietic stem and progenitor cells via CRISPR-Cas9-mediated homology-independent targeted integration.
    Bloomer H; Smith RH; Hakami W; Larochelle A
    Mol Ther; 2021 Apr; 29(4):1611-1624. PubMed ID: 33309880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRIAMF: A New Method for Delivery of Cas9 Ribonucleoprotein Complex to Human Hematopoietic Stem Cells.
    Yen J; Fiorino M; Liu Y; Paula S; Clarkson S; Quinn L; Tschantz WR; Klock H; Guo N; Russ C; Yu VWC; Mickanin C; Stevenson SC; Lee C; Yang Y
    Sci Rep; 2018 Nov; 8(1):16304. PubMed ID: 30389991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins.
    Pavani G; Laurent M; Fabiano A; Cantelli E; Sakkal A; Corre G; Lenting PJ; Concordet JP; Toueille M; Miccio A; Amendola M
    Nat Commun; 2020 Jul; 11(1):3778. PubMed ID: 32728076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and Validation of CRISPR/Cas9 Off-Target Activity in Hematopoietic Stem and Progenitor Cells.
    Park SH; Lee CM; Bao G
    Methods Mol Biol; 2022; 2429():281-306. PubMed ID: 35507169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
    Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
    Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homology-directed gene-editing approaches for hematopoietic stem and progenitor cell gene therapy.
    Azhagiri MKK; Babu P; Venkatesan V; Thangavel S
    Stem Cell Res Ther; 2021 Sep; 12(1):500. PubMed ID: 34503562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9.
    Gundry MC; Brunetti L; Lin A; Mayle AE; Kitano A; Wagner D; Hsu JI; Hoegenauer KA; Rooney CM; Goodell MA; Nakada D
    Cell Rep; 2016 Oct; 17(5):1453-1461. PubMed ID: 27783956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Versatile Tool for the Quantification of CRISPR/Cas9-Induced Genome Editing Events in Human Hematopoietic Cell Lines and Hematopoietic Stem/Progenitor Cells.
    Jayavaradhan R; Pillis DM; Malik P
    J Mol Biol; 2019 Jan; 431(1):102-110. PubMed ID: 29751014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
    Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
    Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies.
    Ureña-Bailén G; Block M; Grandi T; Aivazidou F; Quednau J; Krenz D; Daniel-Moreno A; Lamsfus-Calle A; Epting T; Handgretinger R; Wild S; Mezger M
    CRISPR J; 2023 Feb; 6(1):5-16. PubMed ID: 36662546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells.
    Yudovich D; Bäckström A; Schmiderer L; Žemaitis K; Subramaniam A; Larsson J
    Sci Rep; 2020 Dec; 10(1):22393. PubMed ID: 33372184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications.
    Venkatesan V; Christopher AC; Karuppusamy KV; Babu P; Alagiri MKK; Thangavel S
    J Vis Exp; 2022 Aug; (186):. PubMed ID: 36036597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia.
    Román-Rodríguez FJ; Ugalde L; Álvarez L; Díez B; Ramírez MJ; Risueño C; Cortón M; Bogliolo M; Bernal S; March F; Ayuso C; Hanenberg H; Sevilla J; Rodríguez-Perales S; Torres-Ruiz R; Surrallés J; Bueren JA; Río P
    Cell Stem Cell; 2019 Nov; 25(5):607-621.e7. PubMed ID: 31543367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Knockout in Hematopoietic Stem and Progenitor Cells Followed by Granulocytic Differentiation.
    Mir P; Ritter M; Welte K; Skokowa J; Klimiankou M
    Methods Mol Biol; 2020; 2115():455-469. PubMed ID: 32006417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of CRISPR/HDR editing versus lentiviral transduction on long-term engraftment and clonal dynamics of HSPCs in rhesus macaques.
    Lee BC; Gin A; Wu C; Singh K; Grice M; Mortlock R; Abraham D; Fan X; Zhou Y; AlJanahi A; Choi U; DeRavin SS; Shin T; Hong S; Dunbar CE
    Cell Stem Cell; 2024 Apr; 31(4):455-466.e4. PubMed ID: 38508195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models.
    Demirci S; Khan MBN; Hinojosa G; Le A; Leonard A; Essawi K; Gudmundsdottir B; Liu X; Zeng J; Inam Z; Chu R; Uchida N; Araki D; London E; Butt H; Maitland SA; Bauer DE; Wolfe SA; Larochelle A; Tisdale JF
    Cytotherapy; 2024 Jun; 26(6):641-648. PubMed ID: 38506770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia.
    Tothova Z; Krill-Burger JM; Popova KD; Landers CC; Sievers QL; Yudovich D; Belizaire R; Aster JC; Morgan EA; Tsherniak A; Ebert BL
    Cell Stem Cell; 2017 Oct; 21(4):547-555.e8. PubMed ID: 28985529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PLGA-Nanoparticles for Intracellular Delivery of the CRISPR-Complex to Elevate Fetal Globin Expression in Erythroid Cells.
    Cruz LJ; van Dijk T; Vepris O; Li TMWY; Schomann T; Baldazzi F; Kurita R; Nakamura Y; Grosveld F; Philipsen S; Eich C
    Biomaterials; 2021 Jan; 268():120580. PubMed ID: 33321292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas9-AAV versus lentivector transduction for genome modification of X-linked severe combined immunodeficiency hematopoietic stem cells.
    Brault J; Liu T; Liu S; Lawson A; Choi U; Kozhushko N; Bzhilyanskaya V; Pavel-Dinu M; Meis RJ; Eckhaus MA; Burkett SS; Bosticardo M; Kleinstiver BP; Notarangelo LD; Lazzarotto CR; Tsai SQ; Wu X; Dahl GA; Porteus MH; Malech HL; De Ravin SS
    Front Immunol; 2022; 13():1067417. PubMed ID: 36685559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.